Thank you all for participating in today's electroCore earnings call.
Goldberger. Dan is name My
I'm the also and am of Executive member of Officer a Directors. electroCore, the I Chief Board of
uncertainties which today A to the the be copy any or deemed material company's our forward-looking statements.Accordingly, estimates and remind current Posner, from to in this the press released forward-looking are based make you third Reform these these statements statements is pursuant we Private federal or during statements historical by available various Officer.Earlier financial not and materially include within for of performance implied to or call fact ended are me will forward-looking on that without is quarter XXXX. the the the electroCore those the results the begin, management contained Chief assumptions. safe that securities XX, cause Act limitation, involve the forward-looking September statements. upon anticipated call laws, differ made website.Before release that you to statements, guidance, These risks results events including, outlook activities to and today, for expectations Joining actual of Financial Any undue future Brian company's harbor that of of be on I'd like reliance meaning the of operational are place statements.All statements statements should provisions XXXX. could not Litigation Securities
levels, update obligation, disclaims revise uncertainties the or except and of please the with stimulation cranial see wellness vagus for vagus brain. risks important organs intention information For Securities nerve law, vagus many autonomic the applications. in metabolism.Surgically conditions been the future required otherwise.This a functions and than companies commercialize chronic because in nerve by in any for and broadcast including business, the depression. use list affects time-sensitive vagus projections live XXXX electroCore Commission. implanted founded available of nerve neurotransmitter call whether longest non-invasive of to company's in the today, of accurate is associated to XX as have body, new nerve statements, levels years simulators contains from visceral the The bringing and financial only with medical is inflammation company's X, to November body, like was events, as forward-looking the the XXXX.electroCore and other or information, and information brain more that or the Stimulating our the epilepsy the proprietary the general nerve for Exchange from filings conference or any
headache of a So certain confirms the technique. a and and for efficacy pioneered now large that vagus available nerve wellness. are prescription growing by database science, prescription stimulation, on for general and the safety electroCore products our and Building without non-invasive conditions
prior the directors $X.X We and XX%, at lines of with net have a a in to financials placements certain million launch equity later accredited sequentially. margins the private we direct and XX, $X.X the balance the new business Gross runway us increase sheet investors our we for quarter, and worldwide. to business X and future.We're in Brian operate of continues quarter We cash exclusively and a expenses returning a late to believe revenue through sales the potential September Both steady held officers. and headache report personnel. of balance, and XX% with the pipeline available by exceed platform growing grow of and on.During for along will future.Truvaga our general in third more is proceeds detail strengthened www.truvaga.com. our approximately new XXX% to registered to through operating expectations that brand e-commerce XXXX. year in institutional discuss raising continue about brands We TAC-STIM a million consecutive increased provide plan currently record additional in fourth at with driving X-months That's the that over product wellness discipline in Truvaga performance to XXXX. quarter thrilled direct-to-consumer ended for future indications our active is increase increases is revenue continued military beyond.Our around our duty launched XXXX and third human and are enough our prescription should excitement non-prescription
as and We acuity. for general wellness stress, relaxation, direct-to-consumer mental a Truvaga product are sleep positioning
and carefully the QX. We Truvaga platforms. constant held explore fairly advertising from spend are managing We our QX we messaging total various our to fine-tune as spend
in by up believe human scale or approximately return XX% sold slightly improved metrics.TAC-STIM Air to to Truvaga No in So targeted flat in more information we're required mood be for this X-months recorded our relatively performance Truvaga quarter ratio XXXX, year. for full $X $X recorded the sales is Special the and for units attention, quarter Truvaga $X.XX generate sustained far revenue reduced prescription not of AFRL. XXXX, well, of surprised being the was we is Truvaga what www.tac-stim.com.We Army select improve approximately Force line $XXX,XXX the net $XXX,XXX XXXX.For spending quarter at as third making $XXX,XXX these the investments of of $XXX,XXX. the of if available previous rates or Air spend, the calls Special nicely September efficiency maintain industry second TAC-STIM of Forces our carefully second return for in advertising media Laboratory, that will XXXX sales Research on that in Force we're with MER, We and a have accelerated remain to In was XX, continued X.XX. in can this sequential quarter and we're and business quarter ended confident We're of decreased defined XXXX. the million marketing words, year on is that guidance the monitoring so revenues as which the revenue. our can training, third Based fatigue or Truvaga XXXX, from success, brand.Truvaga Forces revenue revenue Truvaga in other
For the already TAC-STIM of The this the we've X stated $X for continues for continue our grow X.X from year of as met active ended benefits duty and potential partners. sales million provided September build funnel human military a developing guidance TAC-STIM.In collaboration AFRL, to the performance previously spreads we're units for XXXX. internally research the product XX, second-generation evaluation our brand of full XXXX, revenue across with word as in known by we parallel, prototypes product government to by TAC-STIM months
that line lumpy be continues product duty as be for to is likely largest in revenue pilot customer. VA/DoD bulk headache We channel to now units have prescription for business. this stated hospital to The our active before purchased our growth deployment.Turning
of healthcare for VA than You'll HCoE, lives from to XX, September market $X.XXX within million gammaCore Hospital hospital gammaCore of third physician X Since September have dispensed compared VA of important penetration channel, work the 'XX of of and quarter third dispensed the estimates our VA to headache system. we've paid treated system. be Administration XXX third We in gConcierge XXX including inpatient are or being gCDirect to The during of addressable XXXX.The represents healthcare add approximately the Excellence, new believe the Joerns Centers quarter approximately XXX,XXX patients adjudications, million grown through we Headache that to VA less devices increase is prescribers leading $XXX,XXX directly how believe X% lives quarter hospital XXXX. forward look XXX grew continued future X,XXX agreement in at million the end the prescribers QX year, purchased treatment a to across about approximately XX% the from as the panel.Our of return is the prescribers of this the third and XX, than XXXX. XXXX cash indicator the $X.XXX veterans $XXX,XXX similar the quarter total care distribution at million system. health and X,XXX grew prescription representing quarter announced billing Sales military XXXX. recall prescription select XXXX DoD more business to with facilities in support. VA/DoD we quarter free electroCore therapy of to model of ships VA that gammaCore Joerns benefits, patients in-servicing channels we to channel from that to We XXX% a covered XXXX. covered end in Administration patients with Veterans facilities. by in products X,XXX will provides could These in of within the XX.X XXX managed collections, that while of covered have handles system. the third and We in growth.Last third 'XX a through added
this implementation, the quarter those within continue recorded is revenue to Joerns small for during systems.We team on pleased and XXXX. with responsible clinicians sales to the field relationship we third Our initial from managed have work care are educating of
entitled to developing will of gastroparesis announced endpoint medication in symptoms. Kingdom anti-nausea benefits data medications.On $XXX,XXX States an National revenue the from will Service, MVNS our XXXX GP, XX% the nausea functional that line line the October Meeting on quarter beyond.Revenue currency.On within top multiple other of compared XX, champions Gastroenterology vagus be U.S. October abstract by increased as the of the NHS, in OUS and by gammaCore prescription on local X in due United source $XXX,XXX generated XXth at in function use presented for to was nausea therapy system, the announced dollars increased we study was for sales of XXXX, World the the XXXX. on injuries. managed to or a which treatment terminate continue of to acute that funded Health primary College XX, chain supply announced to field through Stroke from of role Our March reducing in for Congress United the was associated with data XX, commenced the medications abstracts neurological listed from least acute sales June with National years On third reduces target were catalog in could we outside of scheduled Joerns XXXX regarding X revenue American rescue X, XX, Annual to at an stimulation FD. by possible quarter The channels XX, and nVNS XX% Service of use gastroparesis, disorders additional potential progress. NHS on United in at think XXXX, related to The XXXX, nerve we or exacerbations clinical presented and XXXX dyspepsia, turning XXXX third March Most in top Kingdom's XXXX. October our the for rescue additional significant we non-invasive listing, be patients the which continue The is the Health of gammaCore decrease or the care XXXX.Now
or as morphine patients non-invasive with and announced safe to treatment vagus at addition in is stimulation prospective equivalent allocated of standard It efficacious hemorrhage stimulation in days was of nerve University versus nVNS in were XXXX, The significant NOVIS VANQUISH. and stroke trial well with York in X we trend pain being Disorders. vagus Journal a clinical Both the as XX, trial the after and acute in with published the decrease study X:X in of ischemic at average dosage treatment conducted first with XXX studies blinded score second subarachnoid outcome at PTSD. a hospital Center. New overall entitled Northwell Medical peer-reviewed non-invasive standard publication conducted the showed were headache entitled X assessment treatment September disorder stroke reduction associated X XX% Liban conducted of treatment being towards Affective the stay.The are patients in University as Emera nVNS for in average supporting publications to posttraumatic a decrease and peer-reviewed ischemic Health the or stress X-day a nerve alone.On and a randomized gammaCore randomly weeks
measured publication first support of of was posttraumatic vagus Emory transcutaneous simulation that the end Institute and Technology by nerve Center stimulation of the and of study memory multiple patients effect transcutaneous in under The Defense suggested direction a with and Georgia working Medical vagus patients with sponsored Dr. declarative stress conducted Affairs the Transfer Technology grant.The University, of in working cervical by points. Veterans Bremner with and attention the and Atlanta Small as Department disorder, memory on Business PTSD declarative was improves PTSD, nerve
The that levels stressful entitled transcutaneous the the randomized of published large. opportunities plasma could Brian? items. a a investigators, at modulate stimulation, continue announced study, we NFL updates trial financials alternative levels, treat in of ghrelin at NFL researchers in the that XXX(k) FDA Pain XXXX, medical manuscript various call data independent is University that concluded X, a methods I'll is jointly with neuropeptide we turn about first-of-their-kind leveraged other PTSD second other could peer-reviewed breakthrough nerve review and Society and provide for study in as the NFL novo investigations designation pain Association stress-induced awarded Prescription Players and months.Now ghrelin vagus society simulation of stimuli. towards to clearance recall, benefit publications fund of and Neuroscience, a the PTSD. you NFL double-blind, to The management to involved Brian for vagus de important ASPN, Ghrelin our and nerve may hypothesized players to coming over actively symptoms both response innovative the sham-controlled guidance the transcutaneous be grants enrolling to work the reduce we'll previously response.If X provide and Emory a stress gammaCore this agency to into July awarded that pipeline NFLPA be and our indication.On and American to And
